|MPN Driver Genes and the Importance of Molecular Genetic Testing |
Aaron T. Gerds, MD
|Release Date: February 17, 2021|
Expiration Date: February 17, 2022
Mutational testing is an integral part of the management of myeloproliferative neoplasms (MPNs), as results from this assessment can both guide treatment selection and provide prognostic information. In this article, Dr. Aaron Gerds discusses best practice regarding the utility of mutational testing in clinical practice when treating patients with MPNs.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
|Begin, Earn CreditView Only, No Credit|